跳到正文
心血管健康证据综述4 分钟阅读

降压可减少心血管事件,无论有无糖尿病,绝对获益相近

MoveVitals 编辑部 · 研究发表 · 解读更新

原文:Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis. · The lancet. Diabetes & endocrinology · 2022 · 论文原文 ↗

先看重点

在51项随机试验、358533名参与者中,收缩压每降低5 mm Hg,主要心血管事件减少(2型糖尿病者风险比0.94,95%置信区间0.91~0.98;无糖尿病者0.89,0.87~0.92)。糖尿病患者的相对获益较弱,但绝对风险降低相近,且这些试验发表于1981年至2014年。

证据类型

证据综述

解读依据

公开摘要

阅读重点

方法与适用范围

研究在问什么

2型糖尿病患者开始降压治疗的阈值是否应与非糖尿病者不同,一直存在争议。作者汇总主要试验的个体参与者数据,按糖尿病状态、基线血压和药物类别,比较降低收缩压对主要心血管事件的效果。

研究了谁,如何研究

对降压治疗试验者协作组(Blood Pressure Lowering Treatment Trialists' Collaboration)数据集中的随机试验做单阶段个体参与者水平数据荟萃分析(PROSPERO CRD42018099283)。符合条件的试验需比较降压药与安慰剂或其他类别降压药,或强化与标准降压策略,有基线糖尿病状态,且每组至少有1000人年随访;仅纳入心力衰竭、短期治疗或急性情境的试验被排除。主要结局为首次主要心血管事件(卒中或脑血管病、缺血性心脏病、导致死亡或住院的心力衰竭),按收缩压每降低5 mm Hg表示。按试验分层的Cox模型给出按糖尿病状态和基线收缩压分层的风险比,Poisson回归估计绝对风险降低,网络荟萃分析比较五类降压药。

主要发现

以下为作者报告的结果。数字须连同人群和不确定性一起阅读。

  1. 1
    分析纳入1981年至2014年发表的51项试验,共358533名参与者(男性占58%),其中103325人(29%)基线时已患2型糖尿病。中位随访4.2年(四分位距3.0~5.0年)。
  2. 2
    收缩压降低5 mm Hg使两组的主要心血管事件风险都降低,糖尿病患者的相对效果较弱(风险比0.94,95%置信区间0.91~0.98),非糖尿病者为风险比0.89(95%置信区间0.87~0.92;交互作用p=0.0013)。
  3. 3
    两组的绝对风险降低没有明显差别,因为糖尿病患者的绝对心血管风险更高。
  4. 4
    没有可靠证据表明两组中治疗效果因基线收缩压而异,五类药物中也没有证据显示相对效果因糖尿病状态而不同。

局限与不确定性

  1. 1
    试验开展于1981年至2014年,当时的糖尿病和心血管基础治疗与现在不同。
  2. 2
    中位随访4.2年可能无法反映更长期的获益或危害,摘要也未报告低血压等不良反应。
  3. 3
    估计值按收缩压每降低5 mm Hg计算,这是一种建模约定,假设不同试验实际达到的降幅效果相似。
  4. 4
    本解读仅基于摘要。

对日常健康的启示

作者的结论是,有无2型糖尿病的人从降压中获得的绝对益处相近,因此不主张按糖尿病状态采用不同的阈值、强度或药物类别。这些是过去试验的人群平均结果,你自己的目标和治疗应与医生一起决定。

如何联系自己的数据

经过验证的上臂式血压计是合适的工具:在每天同一时间、坐位休息后测量,并连续几周记录多次读数。能估测血压的手表不能替代这些试验使用的诊室测量。就诊时带上家庭血压记录。

如何理解这类证据

先看纳入了哪些设计、检索与偏倚评估如何完成,以及检索截止日期;发表新不代表底层证据都是最新的。

作者的结构化摘要 English

以下英文摘要按记录的开放许可转载,属于作者原始材料,不是 MoveVitals 的解读。上方已提供研究解读,分别说明作者结果与本站解释;重要结论可直接核对原文。

Background

Controversy exists as to whether the threshold for blood pressure-lowering treatment should differ between people with and without type 2 diabetes. We aimed to investigate the effects of blood pressure-lowering treatment on the risk of major cardiovascular events by type 2 diabetes status, as well as by baseline levels of systolic blood pressure.

Methods

We conducted a one-stage individual participant-level data meta-analysis of major randomised controlled trials using the Blood Pressure Lowering Treatment Trialists' Collaboration dataset. Trials with information on type 2 diabetes status at baseline were eligible if they compared blood pressure-lowering medications versus placebo or other classes of blood pressure-lowering medications, or an intensive versus a standard blood pressure-lowering strategy, and reported at least 1000 persons-years of follow-up in each group. Trials exclusively on participants with heart failure or with short-term therapies and acute myocardial infarction or other acute settings were excluded. We expressed treatment effect per 5 mm Hg reduction in systolic blood pressure on the risk of developing a major cardiovascular event as the primary outcome, defined as the first occurrence of fatal or non-fatal stroke or cerebrovascular disease, fatal or non-fatal ischaemic heart disease, or heart failure causing death or requiring hospitalisation. Cox proportional hazard models, stratified by trial, were used to estimate hazard ratios (HRs) separately by type 2 diabetes status at baseline, with further stratification by baseline categories of systolic blood pressure (in 10 mm Hg increments from <120 mm Hg to ≥170 mm Hg). To estimate absolute risk reductions, we used a Poisson regression model over the follow-up duration. The effect of each of the five major blood pressure-lowering drug classes, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β blockers, calcium channel blockers, and thiazide diuretics, was estimated using a network meta-analysis framework. This study is registered with PROSPERO, CRD42018099283.

Findings

We included data from 51 randomised clinical trials published between 1981 and 2014 involving 358 533 participants (58% men), among whom 103 325 (29%) had known type 2 diabetes at baseline. The baseline mean systolic/diastolic blood pressure of those with and without type 2 diabetes was 149/84 mm Hg (SD 19/11) and 153/88 mm Hg (SD 21/12), respectively. Over 4·2 years median follow-up (IQR 3·0-5·0), a 5 mm Hg reduction in systolic blood pressure decreased the risk of major cardiovascular events in both groups, but with a weaker relative treatment effect in participants with type 2 diabetes (HR 0·94 [95% CI 0·91-0·98]) compared with those without type 2 diabetes (0·89 [0·87-0·92]; p_(interaction)=0·0013). However, absolute risk reductions did not differ substantially between people with and without type 2 diabetes because of the higher absolute cardiovascular risk among participants with type 2 diabetes. We found no reliable evidence for heterogeneity of treatment effects by baseline systolic blood pressure in either group. In keeping with the primary findings, analysis using stratified network meta-analysis showed no evidence that relative treatment effects differed substantially between participants with type 2 diabetes and those without for any of the drug classes investigated.

Interpretation

Although the relative beneficial effects of blood pressure reduction on major cardiovascular events were weaker in participants with type 2 diabetes than in those without, absolute effects were similar. The difference in relative risk reduction was not related to the baseline blood pressure or allocation to different drug classes. Therefore, the adoption of differential blood pressure thresholds, intensities of blood pressure lowering, or drug classes used in people with and without type 2 diabetes is not warranted.

Funding

British Heart Foundation, UK National Institute for Health Research, and Oxford Martin School.

来源与署名

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.

Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, Davey Smith G, Holman RR, Woodward M, Gupta A, Adler AI, Wamil M, Sattar N, Cushman WC, McManus RJ, Teo K, Davis BR, Chalmers J, Pepine CJ, Rahimi K, Blood Pressure Lowering Treatment Trialists' Collaboration.

The lancet. Diabetes & endocrinology · 2022-07-22

DOI: 10.1016/s2213-8587(22)00172-3 ↗PubMed · 35878651 ↗Europe PMC · 记录的开放许可: cc by ↗

摘要版权归原作者,依据来源记录的开放许可转载。中文译文辅助阅读,英文摘要用于核对术语与具体数值;本站的方法学解释与作者结论分别呈现。

MoveVitals 编辑解读 · 健康教育内容 · 未记录个人临床审阅

来源核验日期 2026-11-01

实用健康指南

放在一起读

·观察研究荟萃分析

昼夜活动节律紊乱与更高的死亡风险相关(109,365人)

在7项观察性研究、共109,365名参与者中,昼夜活动对比较弱(相对振幅较低)与更高的心血管死亡风险(风险比[HR]1.50,95%置信区间1.13至1.98)和全因死亡风险(HR 1.46,95%置信区间1.27至1.68)相关。证据基础小,又是观察性的,不能说明改善节律就能降低风险,疾病本身也可能扰乱节律。

Journal of the American Heart Association

重点论文精讲阅读论文 →
·随机试验荟萃分析

五类运动都降低了静息血压,等长训练降幅最大

汇总270项随机试验、共15,827名参与者的结果,有氧、抗阻、联合、间歇和等长训练与无干预对照组相比都降低了静息血压(各P<0.001),其中等长训练降幅最大:收缩压下降8.24 mm Hg,舒张压下降4.00 mm Hg。各方式之间的排序部分来自间接比较,各试验也不尽相同,所以排序不是个人的运动处方。

British Journal of Sports Medicine

重点论文精讲阅读论文 →
·随机对照试验

盐替代品使中国农村高危人群的卒中、主要心血管事件和死亡率下降

在中国农村600个村庄、20,995名有卒中史或年龄在60岁及以上且有高血压的人中,使用盐替代品(氯化钠75%、氯化钾25%)的卒中发生率低于普通盐:平均随访4.74年,每1000人年29.14次对33.65次(率比0.86,95%置信区间0.77至0.96;P=0.006)。死亡也更低(率比0.88),严重高钾血症事件没有显著增多,但试验为开放标签设计,且在中国农村开展。

The New England Journal of Medicine

重点论文精讲阅读论文 →
·测量验证研究/综述

智能手表脉搏不规则提醒较少见,做贴片检查者34%确有房颤

在419,297名没有已知心房颤动(房颤)的苹果手表用户中,0.52%收到脉搏不规则提醒;返还可用心电贴片的450人中,34%确认有房颤(97.5%置信区间29至39)。提醒发出时恰有贴片记录的,通知的阳性预测值为0.84(95%置信区间0.76至0.92),但收到提醒者中仅20.8%返还了贴片,没有收到提醒的人未被监测,所以手表没有提醒并不能排除房颤。

The New England Journal of Medicine

重点论文精讲阅读论文 →
心血管健康 →